background image for GxP Lifeline
GxP Lifeline
  • 2021-bl-fda-eu-inspections_132x132

    FDA vs. EU Inspections: Similarities and Differences

    In 2009, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) launched an initiative to harmonize regulatory supervision of clinical trials. It streamlines collaboration and information sharing between the two regulatory bodies on good clinical practice (GCP) inspections. Quality and compliance expert Maria Dorat gives an update on the initiative and explains how harmonization is working during COVID-19.

    Full story
  • 2021-bl-qa-cupply-chain_132x132

    Supply Chains Q&A: What to Consider Before Making Changes

    If manufacturers want to move business away from China, or elsewhere, there are important considerations to take into account. Cynthia Kalina-Kaminsky, Ph.D. and owner and consultant for Process & Strategy Solutions, working with Quality Support Group, explains more in this Q&A.

    Full story
  • 2021-bl-supply-chain-adaptability_132x132

    The Botanical Supply Chain Problem of 2021

    The start of the new year was a sign of hope, more so than any other year in recent history. However, even as we wait for things to get better, nutraceutical companies are facing severe supply chain problems due to increases in demand and transportation problems brought on by the pandemic.

    Full story
  • 2020-bl-quality-excellence-02_132x132

    5 Critical Factors in the SMART CAPA Process

    Just as the name implies, corrective and preventive actions (CAPA) requires action. The key is knowing exactly what kind of action to take to solve the problem and prevent it from happening again.

    Full story
  • 2021-bl-5-compliance-mistakes_132x132

    5 Common Compliance Problems and How to Avoid Them

    Five of the most common compliance problems and how to avoid them including documentation issues, lack of quality oversight, neglecting to assess risks, not learning from mistakes, and failure to follow through on commitments.

    Full story
  • 2021-bl-qualitech_132x132

    Artificial Intelligence Pharmaceutical Insights

    AI is moving quickly, and before long, it will play an integral role in the pharmaceutical sector. The benefits of AI include improving efficiency, streamlining production, and shortening the length of time it takes to conduct quality reviews. The result is getting product to market faster.

    Full story
  • 2021-bl-sue-marchant-plenary_132x132

    2021: The Year for Insights Into Quality Data

    The new year might turn out to be just as unpredictable as the old. But, there’s one thing that we at MasterControl have full confidence in: Quality data will become more accessible and provide more insights than ever before.

    Full story
  • 2021-bl-effective-failure-investigation_132x132

    Is Your CAPA Process Providing Adequate Return on Investment? If Not, Why Not?

    The FDA has increased focus on the effectiveness of failure investigations during inspections in recent years. A review of 483 observations and warning letters clearly demonstrate the agency’s current concern about the adequacy of failure investigations to truly identify root cause.

    Full story
  • 2021-bl-measuring-risk-management_132x132

    How to Measure Risk Management Outcomes

    The task of measuring the benefits risk management brings to an organization is a challenging one. To overcome this challenge, the measurement of risk management performance needs to consider a wide range of factors.

    Full story
  • 2021-bl-wellington-foods_132x132

    Quality Is the Key Ingredient to Successful Manufacturing

    The president of Wellington Foods, a leading contract manufacturer of nutraceuticals, explains why quality should be an organization’s top priority. This approach helps manufacturers achieve better process control and plan for significant growth without worrying about highly complex manufacturing processes.

    Full story
  • 2021-bl-ai-emerging-tech_132x132

    3 Practical Ways to Prepare for Pharma’s AI-Driven Future

    Think only big pharma companies with deep pockets can benefit from artificial intelligence and other advanced technologies? Think again. AI is the future of pharma, and nowadays companies of all sizes are starting leverage it to streamline quality processes. Learn the pragmatic steps you can take today to position your company to get good returns on AI investments.

    Full story
  • 2021-bl-investigational-device_132x132

    FDA’s IDE: Data-Centric Approach to Med Device Innovation

    An Investigational Device Exemption (IDE) is a regulatory option that allows an investigational medical device to be used in a clinical study in order to collect safety and effectiveness data. This article explains why medical device manufacturers would seek an IDE and how they apply for the designation.

    Full story
  • 2021-bl-data-driven-quality-model_132x132

    Adopting a Data-Driven Quality Model: Essential for Quality and Compliance

    Life sciences companies have long generated vast amounts of data as a byproduct of their processes for developing and manufacturing products. Quality is one area of the business that is particularly dependent on data. This article explains how companies are emerging as leaders in their industries by implementing a data-driven approach to quality management.

    Full story
  • 2021-bl-understanding-acronyms_132x132

    Making Sense of LIMS, QMS, GMP and Other ERP Acronyms for Life Sciences

    Acronyms can look more like alphabet soup, but here is your cheat sheet to understand some of the most common ones used in life sciences manufacturing: LIMS, QMS, GMP and ERP.

    Full story
  • 2021-bl-global-regulatory-strategy-plan_132x132

    How to Create an Effective Global Regulatory Strategy and Plan

    An integral part of remaining compliant is having and maintaining a strong global regulatory strategy. Before diving in and creating a strategy, understand what to include so it’s effective. A global regulatory strategy ultimately saves your organization time and money while making it possible to get product to market more quickly.

    Full story
  • 2021-bl-spectra-terms-explained-2_132x132

    "Can I get a Translation Please? Tips to Ensuring Productive Communications with Regulatory Authorities, Part Two"

    Understand simple strategies for communicating with your review team to ensure you’re speaking a language that your regulatory authority understands, and more importantly, a language that can get your product to market.

    Full story
  • 2021-bl-spectra-terms-explained_132x132

    Can I get a Translation Please? 3 Tips to Ensure Productive Regulatory Communication, Part One

    Miscommunications can stall regulatory reviews and approvals. Avoid the frustration. In the first half of this two-part series, an expert shares her tips on how to prepare your regulatory submission. The trick is to “translate” your scientific and engineering outcomes so they can be easily understood by regulatory authorities.

    Full story
  • 2020-bl-future-trends-opportunities_132x132

    Future Trends and Opportunities in Quality Assurance

    At a previous PDA/FDA Joint Regulatory Conference in Washington, D.C, Donna Gulbinski, quality and regulatory affairs expert, provided useful information about the future of quality management. She identified some key strategies for how your organization can identify and understand quality assurance trends and develop initiatives for long-term success.

    Full story
  • 2020-bl-alan-rencher-highlights_132x132

    How a Force Multiplier Elevates Your Organization’s Success

    At MasterControl’s Virtual Masters Summit 2020, vice president of engineering Alan Rencher provided valuable insight about force multiplication and how it gives companies the ability to seamlessly integrate business units, excel in all aspects of operations and sustain a competitive advantage.

    Full story
  • 2020-bl-supply-chain-optimization_132x132

    2021 is the Year of Supply Chain Optimization

    In the wake of a global pandemic, supply chain disruptions that were once inconveniences have become existential threats to many life sciences companies. Learn the steps your organization can take to build a more resilient supplier ecosystem.

    Full story
[ { "key": "fid#1", "value": ["GxP Lifeline Blog"] } ]